# PROTECTING INNOVATION INTERNATIONALLY

# PATENT STRATEGY IN VIEW OF DIFFERENT LEGAL REGIMES IN EUROPE AND THE USA

Ilya Kalnish
Partner, Patent Agent, Trademark Agent
Skolkovo Patent School – September 2017



# A FEW WORDS ABOUT US

# **BCF LLP**

**Business law** 

# Canadian, U.S., European, U.K. Patent Agents/Attorneys

# **Ilya Kalnish**

Software/IT, Telecom, Mechanical

- Over 10 years in-house experience
- Managed patent procurement and enforcement around the world
- Over 4 years private practice experience
  - Bringing business focus into patent protection of inventions
  - Representing both large international corporations and SME/start-ups





# PRESENTATION OVERVIEW

# **CHAPTERS**

**Overview of international patent systems** 

Selecting your international patent strategy – key considerations

Considering key differences between European and US patent systems when preparing your patent application

Special considerations for patent applications originating from Russian applicants / inventors



# **KEY TAKEAWAYS**

- Patent is a business tool
- Patent strategy should be closely aligned with the business objectives for the technology
- Claimed subject matter should be revisited periodically throughout the patent application life cycle to ensure alignment with business objectives
- An early investment in a solid International/US/EP patent and protection strategy can pay dividends in the long run

MANAGE YOUR INTERNATIONAL PATENT ASSETS WISELY TO SUPPORT YOUR BUSINESS GOALS!



# OVERVIEW OF INTERNATIONAL PATENT SYSTEMS



# **OVERVIEW OF INTERNATIONAL SYSTEMS**

- Patents, for the most part, are creatures of national laws – they are obtained and enforced in accordance with national laws and regulations.
- Even though national laws "sound" the same, the specific requirements for obtaining patents can vary drastically:
  - Patentable subject matter, interpretation of patentability requirements (especially obviousness), written description and support requirements
- Several international treaties exist in an attempt to harmonize patent regimes around the world.



# INTERNATIONAL PATENT SYSTEM

# **PATENTS and DESIGNS**

- Paris Convention
- Patent Co-operation Treaty
- EPO (European Patent Convention)
  - London Agreement
  - Unified European Patent / Unified European Court System
     NEW!!!
- EAPO (Eurasian Patent System)



# **INTERNATIONAL PATENT SYSTEM (CONT.)**

- ARIPO (African Regional Intellectual Property Organization)
- OAPI (Organisation Africaine de la Propriété Intellectuelle )
- Trans Tasman Mutual Recognition treaty
- Hague Agreement
  - Geneva Act (WIPO)

# TRADEMARKS AND COPYRIGHT

- Madrid Protocol / Madrid Agreement
- Berne Convention



# PATENT CO-OPERATION TREATY (PCT)

- The Patent Co-operation Treaty, called PCT for short, is an international patent <u>examination</u> system that first came into existence in 1978.
- Administered by the World Intellectual Property Organization (WIPO), a specialized agency of the United Nations, headquartered in Geneva, Switzerland.
- Currently includes <u>152 contracting states</u> (newest member- Jordan) and <u>4 regional patent organizations</u>.
- Some key jurisdictions are <u>not</u> part of PCT:
  - <u>Taiwan</u> (not part of the Paris convention either), <u>Argentina</u>,
     <u>Venezuela</u>, <u>Uruguay</u>




# PATENT CO-OPERATION TREATY (PCT)

- The PCT system is available for filing patents and utility models, not for designs (Hague) or trademarks (Madrid).
- The PCT system is a patent filing system, not a "granting" system: it provides an international patent searching and/or examination.
- Individual countries still need to individually grant the final patent.



# PCT APPLICATION PROSECUTION





# PATENT CO-OPERATION TREATY (PCT)

# **Benefits of the PCT filing:**

- One application in one language can be filed to secure a filing date internationally.
- Control of early prosecution is held in fewer hands.
- Fee may be reduced at national phase entry from PCT in some jurisdictions (compared to direct filing in each jurisdiction).
- Decisions on foreign filings can be postponed up to 30 months from first (local) filing.
  - This may also be advantageous to give time for the technology to mature before investing in each jurisdiction.



# PCT APPLICATION PROSECUTION

# Amendments to the PCT Application available during prosecution (at least twice):

### Article 19

- Must be made by the 16<sup>th</sup> month after the original filing, or two months after the International Search Report is issued (whichever is later).
- Amendments can only be made to the claims.
- These amendments must be filed with the International Bureau (not with the Receiving Office).

# Article 34

- Amendments can only be made if requesting Examination under Chapter II (which is optional and incurs additional costs).
- Amendments must be made by the 22<sup>nd</sup> month after original filing.
- Amendments can be made to any of the claims, description, and figures.
- Depending on the timing, several rounds of prosecution may be possible.



# SELECTING INTERNATIONAL PATENT STRATEGY — KEY CONSIDERATIONS



# There can be several different approaches to foreign filing strategies, including:

- Filing in a limited number of selected jurisdictions directly.
- Filing a local or provisional application, then (within 12 months) filing in selected juridictions directly.
- Filing a local or provisional application, then (within 12 months) filing a PCT application, then (within 30 months of original filing) filing national entries.





### **Benefits:**

- Ability to get the patent grant ASAP
- Cost "savings" for international route avoidance

### **Applicability:**

- Russia first filed jurisdiction (wait 6 months for foreign filing license or petition for early secrecy examination)
- Important technology
- Crowded market space with many copy cats
- Technologies with short life cycles





### **Benefits:**

- Ability to incorporate new embodiments within the priority year
- Ability to "draw the line in the sand"
- Ability to get most broad coverage / claim construction

### **Applicability:**

- Forward looking technologies
- Ground-breaking innovation
- Technologies with iterative development process





### **Benefits:**


- Ability to defer major costs towards later stage of patent life cycle
- Ability to "buy" more decision-making time
- Ability to amend claims at a single point through PCT
- Ability to use PCT-based PPH system to expedite examination

# **Applicability:**

- Potentially important innovation
- Innovation, which business importance may not be clear from day one



# FOREIGN STRATEGY – KEY CONSIDERATIONS





# FOREIGN STRATEGY – KEY CONSIDERATIONS

- Budget / Value of the patent
- Product life cycle
- Geographical footprint of the invention
- Marketing roadmap
- Competitive conditions
- Who is the potential infringer (claims in the country)
- National laws and enforcement practices



# FOREIGN STRATEGY – KEY CONSIDERATIONS

# Foreign patent protection is expensive:

- Higher government fees
- Translation costs (especially if translated into multiple languages)
- Foreign attorneys' fees



# FOREIGN STRATEGY — FEE COMPARISON: EP —US

	Europe	United States
Filing Fees	~\$2400 (USD)	\$1600 (USD)
Discounts	None	Small Entity (-50%) Micro Entity (-75%)
<b>Excess Claim Fees</b>	Yes >15 claims (expensive)	Yes > 20 claims (relatively inexpensive)
Multiple Dependencies	Allowed, very commonly used	Not generally used due to large fees incurred (no multiple on multiple)
Request Examination	Yes, ~\$2000 (USD)	No
Application Maintenance Fees	Annually from 2 <sup>nd</sup> year - start at ~\$570 (USD)	No
Patent Maintenance Fees	<ul><li>(1) Payable to national patent office for each validated patent, OR</li><li>(2) UP renewal fee</li></ul>	Due at 3½, 7½, and 11½ years (\$1600, \$3600, \$7400 USD)

# FOREIGN STRATEGY — STRATEGY TRADE-OFFS

# Idea of coverage trade-offs

- Cheap <u>vs.</u> expensive jurisdictions (for example, Japanese application filed through associate vs. Canadian application filed in-house).
- Focused claim set <u>vs.</u> extensive part-subsystem-system claim set (evaluate value of the case, where possible).
- Focused international filing <u>vs.</u> extensive number of filings in selected jurisdictions.



# FOREIGN FILING STRATEGY— PATENT PROSECUTION HIGHWAY

# Patent Prosecution Highway (PPH) — Fast Track Examination

- Participating offices agree to fast-track examination for applications that have recieved a positive patentability report from another participating office.
- Applying for fast-track examination based on a PPH request provides accelerated examination without a fee.
- Positive Written Opinions and Preliminary Reports on Patentability from PCT prosecution often satisfy the positive patentability report requirement for requesting PPH.




# FOREIGN FILING STRATEGY — FAST TRACK EXAMINATION WITH PPH

# Examples of PPH agreements as of 2015

(PPH Mottainai is PPH 2.0- improved agreements)

Illustration produced by the Japanese Patent Office (JPO)





# FOREIGN FILING STRATEGY— TYPES OF PROTECTION

# Utility patent

Basic patent – "standard" patent

# Utility model

- Also sometimes called innovation patent
- Usually less stringent requirements (in many countries, formalities and/or novelty examination only)
- Usually has a shorter term of protection
- Some versions available in many jurisdictions, including:
  - China
  - Taiwan
  - Germany
  - Japan



# FOREIGN FILING STRATEGY— TYPES OF PROTECTION

# Dual strategy

- China, TW
- Applying for both utility model and utility patent
- Covers different (or even the same) aspect of the technology
- Has different stringency of examination
- But also different terms of protection (10 vs 20 years China)

# Typical use

- File same spec as utility model and utility patent
- Utility model is typically granted fast early protection against infringers
- When the utility patent is allowed, the applicant can abandon the granted utility model in favor of the utility patent



# KEY DIFFERENCES BETWEEN EUROPEAN AND US PATENT SYSTEMS



# **OVERVIEW OF THE U.S. PATENT SYSTEM**

### **Common law-based**

- Role of precedent: binding court decisions
- As a result, US patent practice is "reactive"

# Geared towards litigation

- Person of ordinary skill in the art (POSITA) vs. Judge vs. Jury
- Post-AIA office-based challenges to patents

"Administered" by lawyers and not necessarily "technical" persons

■ Not all lawyers/judges/ jurors involved in patent disputes have a technical training



# OVERVIEW OF THE EUROPEAN PATENT SYSTEM

### Civil law-based

- Limited binding power of precedents (e.g. G decisions)
- Relatively slow changing system / grounded in EPO convention

# Enforcement is national

- EPO based opposition (some inconsistencies between boards)
- Enforcement in national states harmonized law, applications may vary)\*

"Administered" by patent attorneys and "technical" persons (judges, examiners)

- Brings "final" evaluation of patentability more upfront (Patent Office rather than Court)
- Technical Judges



In a constant state of development in the US, well settled in Europe

### **USA EPO** > Article 35 U.S.C. §101 of the United > Article 52 (2) of the European States Patent Law defines four Patent Convention lists subject matter that, considered as such, is categories of patentable inventions: process, machine, manufacture **not** patent-eligible. and composition of matter. > The list of exclusions recites: > This list is exhaustive. Discoveries, scientific theories and mathematical methods; Statutory law of the United States does not define any exclusions from Aesthetic creations; patentability: abstract ideas, Schemes, rules and methods for natural phenomena and laws of performing mental acts, playing nature. games or doing business, and computer programs (per se); Presentations of information.



RECENT U.S. SUPREME COURT DECISIONS: FOCUS ON SUBJECT MATTER & OBVIOUSNESS

# **BUSINESS METHODS/IT PATENTS after**

• Alice Corp. v. CLS Bank, 134 S.Ct. 2347 (2014)

### **DNA** after

• Int'lAss'n for MolecularPathology v. MyriadGenetics, Inc., 133 S.Ct. 2107 (2013)

### **DIAGNOSTIC METHODS after**

• Mayo Collaborative Servs. v. PrometheusLabs., Inc., 32 S.Ct. 1289 (2012)



### **Software - USA**

The USPTO guidelines provide examples of the limitations that were held to be insufficient to qualify as "significantly more", when recited in a claim that included a judicial exception:

- Performing repetitive calculations
- Receiving, processing and storing data
- Scanning or electronically retrieving data from a physical document
- Electronic recordkeeping
- Automating mental tasks
- Receiving and transmitting data through a network



**Software - EPO** 

# Concept of "technical character" / further technical effect:

- Computer programs <u>as such</u> are not patentable.
- For software-implemented inventions, reciting a computer generally provides technical character.
- Need for (further) technical effect:
  - Compare a program that performs calculations to control an industrial process or an autopilot of a car vs. a program that organizes images on a screen of a computer to make them easier to be appreciated by the user.



# PATENT PROSECUTION

### **USPTO and EPO**

USA	<b>EPO</b>
<ul> <li>1-year grace period</li> <li>Multiple ways to enter the USPTO (NPE, CON, US as first filed)</li> <li>Internal priority is available</li> <li>Provisional patent applications are available</li> </ul>	<ul> <li>6-month grace period in very limited circumstances</li> <li>Direct file at the EPO, RPE entry into EPO, NPE entry in certain EP individual states has been closed</li> <li>Internal priority is available</li> <li>Provisional patent applications are not available</li> </ul>



# PATENT PROSECUTION

### **USPTO and EPO**

USA	<b>EPO</b>
<ul> <li>Enablement requirement</li> </ul>	<ul><li>Sufficiency</li></ul>
<ul> <li>Written description requirement</li> </ul>	<ul><li>Clarity</li></ul>
<ul> <li>Multiple embodiments – support for claim amendments and broad claim construction</li> </ul>	<ul> <li>Claim language should be clear "on its face" with no recourse to the description</li> </ul>
<ul> <li>Claims are construed with an eye to the description, hence description is as important as claims</li> </ul>	<ul> <li>Multiple embodiments, but all specific desired combination must be described</li> <li>No cherry picking</li> </ul>



# **PATENT PROSECUTION**

#### **USPTO and EPO**

USA	<b>EPO</b>
<ul> <li>Support for amendments can be derived from the description and figures as filed</li> </ul>	<ul> <li>Very strict rules for amendment support, close to literal support is required</li> </ul>
<ul> <li>As long as multiple embodiments are described in the application as filed, support can be found for virtually any amendment that is reasonably supported by the embodiments described</li> </ul>	<ul> <li>"Unambiguously Derivable" test for determining if support for amendments exists is applied</li> <li>Extremely strict rules against "cherry picking" amongst various embodiments provided</li> <li>Can not combine claims unless such combination is expressly disclosed</li> </ul>
	<ul><li>"Inescapable trap"</li></ul>



# **CLAIMS**

#### **USPTO and EPO**

USA	EPO
<ul> <li>Fence-style claiming</li> <li>Single-part claim format</li> <li>Cascading depending claim, each introducing a single narrowing feature</li> <li>No multiple dependent claims</li> <li>Multiple IND claims are permitted (but likely to be divided out)</li> <li>20 claims (with 3 IND) are "included" in the filing fee</li> <li>Single entity claims for distributed methods!!!</li> </ul>	<ul> <li>A mix of fence-style and point-style claiming</li> <li>2-part claim format (preferred by the EPO, but not mandatory)</li> <li>Multiple-dependent claims</li> <li>Claims that include multiple alternatives within a single claim</li> <li>Single IND claim in each category</li> <li>With the exception of server/client device</li> <li>15 claims are "included" in the filing fees, excess claim fees for claims exceeding 15</li> </ul>



# **PATENT CHALLENGES**

#### **USPTO and EPO**

USA	EPO
<ul> <li>Post-AIA USPTO based challenge</li></ul>	<ul> <li>9-month post-grant EPO challenge</li></ul>
procedures (PGR and IPR)	("opposition")
<ul> <li>The patent office invalidation rate</li></ul>	<ul> <li>Regular practice for European</li></ul>
of patents in these procedures is	companies to oppose applications
very high	published for grant



## **PATENT ENFORCEMENT**

## **Claim Construction / claim scope / inequitable conduct**

USA	<b>EPO</b>
<ul> <li>Doctrine of "unclean hands" / inequitable conduct / unenforceability of patents</li> <li>Statements made in prosecution both in the US and abroad</li> <li>Requirement to submit prior art (Information Disclosure Statement)</li> </ul>	<ul> <li>No doctrine of inequitable conduct</li> <li>No requirements to submit prior art to the EPO</li> <li>Applicants can take more creative approach to prosecution, for example, applying the "problem-solution" statement</li> </ul>
<ul> <li>Somewhat narrow application of Doctrine of Equivalents (DOE), which is strictly narrowed by a Prosecution History Estoppel</li> </ul>	<ul> <li>Depending on the jurisdiction of the Court, DOE is very liberally applied (for example, Germany vs England)</li> <li>Depending on the jurisdiction of the Court, no Prosecution History Estoppel (with some deference to statements made in Opposition)</li> </ul>



**Software - recommendations** 

## Considerations when drafting the priority case:

- Provide detailed description of the algorithm
  - Not sufficient to describe WHAT the software does, it is critical to describe HOW the software does it
- Outline non-limiting examples of technical effects achieved by the software
  - Software should solve a computer-centric problem
  - If possible, outline an additional technical effect (not essential in computer being essentially fast at performing calculations) – focus should be on the computer benefits and not user benefits, where possible



#### **Software - recommendations**

- Provide detailed block-diagram of the algorithm with detailed step-by-step description thereof
- Provide multiple alternative embodiments for the US
- Provide ample literal support for amendments in Europe and fall-back positions in prosecution
- Remove (at least in alternative) dependence on operator / user decision
- Describe multiple claims with multiple cascading dependent claims
  - Consider budget and the excess claim fees in Europe / US
  - Draft as many claims as the budget will allow!



#### **Pharma / Life Sciences**

- Very difficult to get life science claim without any experimental data <u>at filing</u>
- Determination is fact specific; no general rule
- Human clinical data generally not required (but the link to human needs to be established)
- If invention is based on improved efficacy, need strong data to support such efficacy
- If advantage is reduced side effects, may need clinical data comparing/showing same
- Novel compound claims generally easier than used claims

A balance between sufficiency of experimental data and need to establish early filing date in view of third parties' disclosures!



#### **Pharma / Life Sciences**

- Need support in the application as filed ideally the first-filed (priority) application
- Need both "literal" support and data
- Description must support the entire breadth of the claims
- Example:
  - "The reaction is run at 60°C." vs.
  - "The reaction can be run at a temperature in the range of about 50-about 70oC, for example at about 50, about 55, about 60, about 65, or at about 70°C."
- Need many different embodiments in description to support broad claims
- Best to include many different claims of varying scope
- Post-filing data <u>may</u> be helpful



**SPECIAL CONSIDERATIONS FOR PATENT APPLICATIONS ORIGINATING** FROM RUSSIAN **APPLICANTS / INVENTORS** 



## RECOMMENDATIONS



#### FOR RUSSIAN-ORIGINATING APPLICATIONS

- Russian patent law and practice are very different from US / EPO patent law and practice.
- Russian and English languages are very different from one another.
- Unless you are looking just for a US / EPO filing for a reason other than to obtain a broad, qualitydrafted patent, a simple translation of the Russian original patent application will not suffice.



## RECOMMENDATIONS



#### FOR RUSSIAN-ORIGINATING APPLICATIONS

- Do NOT wait until the end of the 12-month priority period to start working on the US / EPO patent application.
  - Start Early!
- Unless your English is fluent, work with a fully bilingual patent attorney.
  - They will be able to read the original Russian draft and speak with you in Russian (no translations are necessary).
  - They will be able to prepare the US / EPO patent application in English.



## RECOMMENDATIONS



#### FOR RUSSIAN-ORIGINATING APPLICATIONS

- Be prepared to provide the US / EPO patent attorney with a lot of information regarding the technology.
- The US / EPO patent application will require many more details and many more examples than the Russian application did.
  - This is generally true in US / EPO patent law.
  - It is <u>especially true</u> right now in US software / pharma patent applications given the uncertainty of how the law will develop.



# ТНАПК YOU! СПАСИБО!

#### **Ilya Kalnish**

Partner, Patent Agent, Trademark Agent **Skolkovo Patent School** – September 2017

ilya.kalnish@bcf.ca

